The estimated Net Worth of Arnold L Oronsky is at least $9.49 millió dollars as of 25 September 2020. Mr. Oronsky owns over 55,000 units of KalVista Pharmaceuticals Inc stock worth over $589,600 and over the last 21 years he sold KALV stock worth over $8,792,432. In addition, he makes $109,919 as Independent Director at KalVista Pharmaceuticals Inc.
Sign up
Mr. Oronsky KALV stock SEC Form 4 insiders trading
Arnold has made over 8 trades of the KalVista Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 55,000 units of KALV stock worth $990,000 on 25 September 2020.
The largest trade he's ever made was selling 244,661 units of KalVista Pharmaceuticals Inc stock on 24 November 2004 worth over $1,492,432. On average, Arnold trades about 22,006 units every 129 days since 2004. As of 25 September 2020 he still owns at least 55,000 units of KalVista Pharmaceuticals Inc stock.
You can see the complete history of Mr. Oronsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Arnold Oronsky biography
Arnold L. Oronsky Ph.D. serves as Independent Director of the Company. Dr. Oronsky has served as a member of our Board since November 2016. Dr. Oronsky has been a full-time member of InterWest’s healthcare team since 1994, where he currently serves as a Senior Partner. In addition to being a Senior Partner at InterWest, Dr. Oronsky also serves as a Senior Lecturer in the Department of Medicine at Johns Hopkins Medical School. He is a member of the board of directors of Dynavax Technologies and a number of private pharmaceutical companies. Dr. Oronsky was formerly Vice President for Discovery Research for the Lederle Laboratories division of American Cyanamid Company where he directed all of the research for new drugs and supervised approximately three hundred employees. Dr. Oronsky holds a Ph.D. in Immunology from Columbia University and has published over 125 scientific articles. Oronsky is qualified to serve on our Board because of his lengthy experience in the biotech industry as an investor and public company Board member.
What is the salary of Arnold Oronsky?
As the Independent Director of KalVista Pharmaceuticals Inc, the total compensation of Arnold Oronsky at KalVista Pharmaceuticals Inc is $109,919. There are 8 executives at KalVista Pharmaceuticals Inc getting paid more, with Thomas Crockett having the highest compensation of $1,731,160.
How old is Arnold Oronsky?
Arnold Oronsky is 80, he's been the Independent Director of KalVista Pharmaceuticals Inc since 2016. There are no older and 17 younger executives at KalVista Pharmaceuticals Inc.
What's Arnold Oronsky's mailing address?
Arnold's mailing address filed with the SEC is C/O INTERWEST, 2710 SAND HILL ROAD 2ND FLOOR, MENLO PARK, CA, 94025.
Insiders trading at KalVista Pharmaceuticals Inc
Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ... és Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.
What does KalVista Pharmaceuticals Inc do?
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
What does KalVista Pharmaceuticals Inc's logo look like?
Complete history of Mr. Oronsky stock trades at Applied Genetic Technologies Corp, Dynavax Technologies, KalVista Pharmaceuticals Inc, Macrogenics Inc és Pmv Pharmaceuticals Inc
KalVista Pharmaceuticals Inc executives and stock owners
KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Thomas Crockett,
Chief Executive Officer, Director -
Edward Feener,
Chief Scientific Officer -
Benjamin Palleiko,
Chief Financial Officer, Chief Business Officer -
Thomas Andrew Crockett M.B.A.,
CEO & Director -
Christopher Yea,
Chief Development Officer -
Benjamin L. Palleiko,
Chief Bus. Officer & CFO -
Dr. Christopher M. Yea Ph.D.,
Chief Devel. Officer -
Martin Edwards,
Independent Chairman of the Board -
Edward Unkart,
Independent Director -
Arnold Oronsky,
Independent Director -
Albert Cha,
Independent Director -
Brian Pereira,
Independent Director -
Daniel Soland,
Independent Director -
Michael Smith,
Senior Vice President - Development -
Andreas Maetzel,
Senior Vice President - Medical -
Jarrod Aldom,
VP of Corp. Communications -
John B. McKune,
VP of Fin. -
Stephen Donnelly,
Director of Fin. and Company Sec. -
Dr. Paul K. Audhya M.B.A., M.D.,
Chief Medical Officer -
Dr. Michael D. Smith Pharm.D.,
Sr. VP of Devel. -
Rachel Morten,
Head of Regulatory Affairs and QA -
Leah Monteiro,
Sr. Director of Corp. Communications & Investor Relations -
Dr. Edward P. Feener Ph.D.,
Chief Scientific Officer -
Joshua Resnick,
Director -
Iv, Llcsv Life Sciences Fun...,
-
Capital Management, Llc Kol...,
-
Capital Management, L.P.Ra ...,
-
Rajeev M. Shah,
Director -
Healthcare Capital Partners...,
-
Holdings A/S Novo,
10% owner -
William Fairey,
-
Paul K. Audhya,
CHIEF MEDICAL OFFICER -
Healthcare Capital Partners...,
-
Nancy Stuart,
Director -
Patrick Treanor,
Director -
Brian Piekos,
Chief Financial Officer -
Healthcare Capital Partners...,